Acurx Pharmaceuticals granted new U.S. patent for DNA Polymerase IIIC inhibitors.

Acurx Pharmaceuticals has received a new US patent for DNA Polymerase IIIC inhibitors, including compositions-of-matter, methods of use, and pharmaceutical compositions. This patent strengthens the company's intellectual property portfolio and is the latest addition to its series of granted patents in the US and abroad. Acurx has secured four US patents and granted patents in Israel, Japan, India, and Australia, with additional country-level patent applications under review.